Methods for the treatment of cancer using microtubule targeting agents in combination with immune checkpoint modulators
Combining 2-(difluoromethoxy)-N-[[5-(2-methoxyphenyl)-1H-1,2,4-triazol-3-yl]methyl]benzamide with immune checkpoint modulators enhances cancer treatment efficacy, addressing chemotherapy side effects and overcoming taxane-resistant cancers.
WO2026097102A1PCT designated stage Publication Date: 2026-05-07BPGBIO INC
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- BPGBIO INC
- Filing Date
- 2025-11-04
- Publication Date
- 2026-05-07
Smart Images
Figure US2025054059_07052026_PF_FP_ABST
Abstract
Provided are methods for treating cancers using a compound of Formula I, e.g., 2- (difluoromethoxy)-N-[[5-(2-methoxyphenyl)-1lH-1,2,4-triazol-3-yl]methyl]benzamide, or a pharmaceutically acceptable salt thereof, and at least one immune checkpoint modulator of an immune checkpoint molecule.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators
US20220096400A1
Microtubule targeting agents
US20240342138A1